

Roche's Announcement Regarding Vamikibart (Presentation of New Data in Noninfectious Uveitic Macular Edema)

TOKYO, October 20, 2025 -- [Chugai Pharmaceutical Co., Ltd.](#) (TOKYO: 4519) announced that Roche issued a press release on October 17, regarding vamikibart of the latest data from two global Phase III clinical trials (MEERKAT and SANDCAT) in noninfectious uveitic macular edema (UME), presented at the American Academy of Ophthalmology (AAO) 2025.

Please refer to the link below for details of the press release:

Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss

<https://www.roche.com/media/releases/med-cor-2025-10-17b>

###